What Is mRNA?

mRNA, or messenger RNA, is the class of ribonucleic acid that carries protein-coding information from a gene in the nucleus to the ribosomes in the cytoplasm, where that information is read and translated into a polypeptide chain. It is the intermediate step in the flow of genetic information from DNA to protein, and its existence was proposed and demonstrated in 1961 by François Jacob, Sydney Brenner, and Matthew Meselson, who showed that a short-lived RNA species, rather than the ribosome itself, specified which protein was made.

Structurally, a mature eukaryotic mRNA is a single strand with four functional parts: a 7-methylguanosine cap at the 5' end, an untranslated leader region, an open reading frame consisting of codons that specify amino acids, and a 3' untranslated region ending in a polyadenylate tail. Each element does specific work. The cap recruits translation initiation factors and protects against exonucleases, the untranslated regions bind regulatory proteins and microRNAs, and the poly(A) tail governs stability and translational efficiency.

Transcription and Processing

RNA polymerase II synthesizes a primary transcript from the template DNA strand, reading it in the 3' to 5' direction and building RNA 5' to 3'. In eukaryotes that transcript is extensively processed before it leaves the nucleus. Capping occurs co-transcriptionally after roughly 25 nucleotides. Splicing removes introns and joins exons, and alternative splice site selection lets one gene yield several distinct mRNAs and therefore several protein isoforms. Cleavage and polyadenylation define the 3' end. Chemical modification adds another layer, with N6-methyladenosine and pseudouridine among the marks that influence export, stability, and translation.

Translation and Turnover

Translation begins when the small ribosomal subunit is loaded at the cap and scans to the first suitable start codon, at which point the large subunit joins and elongation proceeds one codon at a time until a stop codon triggers release. Because a single transcript can be read by many ribosomes simultaneously in a polysome, one mRNA molecule can produce hundreds of protein copies. Abundance is set by the balance between synthesis and decay: deadenylation followed by decapping and exonucleolytic digestion is the main degradation route, and surveillance pathways such as nonsense-mediated decay destroy transcripts carrying premature stop codons. Bacterial mRNA half-lives are measured in minutes, mammalian ones in hours, which is why transcript levels can respond quickly to changing conditions.

Synthetic mRNA as a Therapeutic Platform

In vitro transcription produces synthetic mRNA from a DNA template using a phage polymerase, with modified nucleosides such as N1-methylpseudouridine substituted to reduce innate immune recognition and raise protein yield. Delivered into cells, usually inside a lipid nanoparticle, the transcript is translated in the cytoplasm without entering the nucleus or integrating into the genome, and expression is transient. A widely cited review describing mRNA vaccines as a new approach in vaccinology sets out the design choices involved: sequence optimization, purification to remove double-stranded byproducts, and formulation chemistry.

The approach reached large-scale use with SARS-CoV-2 vaccines, and analyses of mRNA technology as a platform for coronavirus vaccine development describe how the same manufacturing line can be redirected to a new antigen by changing only the template sequence. Self-amplifying constructs derived from alphavirus replicons extend expression at lower doses, and work on in vitro transcribed RNA-based platform vaccines and on broad-spectrum mRNA vaccine design examines antigen selection strategies intended to cover variant families rather than single strains.

Applications

mRNA has applications across biology, medicine, and biotechnology, including:

• Prophylactic vaccines against infectious disease
• Therapeutic cancer vaccines and encoded immunomodulators
• Protein replacement therapy for enzyme deficiencies
• Delivery of gene editing components such as Cas nucleases
• Transcriptomic measurement by RNA sequencing and quantitative PCR
• Cell reprogramming and engineered cell therapy manufacturing